Skip to content
Oriol Mirallas MD· @DrMirallas · X·· 2026-04-20Score60

zedoresertib

Reading

Medicinal chemistry beyond KRAS: CDK2, WEE1, SERD

zedoresertib · A WEE1-path molecule on the floor

Body

#AACR26
New frontiers in oncology

Zedoresertib+Lunresertib #CCNE1 #FBXW7 #PPP2R1A
Dr.Yap
@UTMDAnderson

ORR 25% if #CCNE1
Ovarian ORR 50% at MTD2, if #CCNE1 60%
31% on trial >16w
Rash, fatigue, N/V

Dr. Moore
@StephensonCC

Optimal dose

@OncoAlert

@AACR

Heat 11 · 6 likes · 1 reply · 4 reposts

Conference abstracts
CT022NCT04855656matched by 摘要号 CT022
First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations

Timothy A. Yap, Rahul Aggarwal, Elisa Fontana, Martin Hojgaard, Benedito A. Carneiro, Linda Duska, Patricia LoRusso, Siddhartha Yadav, Stephanie Lheureux, Cara Mathews, Ryan H. Moy, Nehal Lakhani, Mia Weiss, Joan Tymon-Rosario, Gerardo Colon-Otero, Ignacio Garrido-Laguna, Elisabeth K. Lee, Esteban Rodrigo Imedio, Jonathan Wessen, Luke Piggott, Vito Dozio, Noemie Luong, Christophe Mas, Alison M. Schram

Read the abstract →

Source: Oriol Mirallas MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org